Medpace Holdings Shares Fall 11% After Company Reports 3Q Results

Dow Jones

Oct 22, 2024

By Stephen Nakrosis

Shares of Medpace Holdings were in the red in the after-hours market following the release of third-quarter financial results that showed the company raising its earnings-per-share guidance and cutting its revenue guidance for 2024.

After the bell, shares of the clinical contract research organization fell 11% to trade at $313.65. The stock finished Monday's regular session with a loss of less than 1%, closing at $352.92.

After the bell, Medpace reported third-quarter earnings per share of $3.01 on revenue of $533.3 million. In the year-ago period, the company reported EPS of $2.22 on revenue of $492.5 million.

The company also reported third-quarter net new business awards of $533.7 million, down from $611.5 million in the year-ago period.

The company said it was expecting 2024 revenue in the range of $2.09 billion to $2.13 billion, below prior guidance of a range between $2.125 billion and $2.175 billion. Also, Medpace said it was expecting 2024 EPS of $11.71 to $12.09. Previously, the company guided for 2024 EPS of $11.24 to $11.93.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 21, 2024 18:54 ET (22:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2477430098"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477430098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477430098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 06:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477430098","market":"us","top_or_hot":-1,"title":"Medpace Holdings Shares Fall 11% After Company Reports 3Q Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Medpace Holdings were in the red in the after-hours market following the release of third-quarter financial results that showed the company raising its earnings-per-share guidance and cutting its revenue guidance for 2024. \n</p>\n<p>\n  After the bell, shares of the clinical contract research organization fell 11% to trade at $313.65. The stock finished Monday's regular session with a loss of less than 1%, closing at $352.92. \n</p>\n<p>\n  After the bell, Medpace reported third-quarter earnings per share of $3.01 on revenue of $533.3 million. In the year-ago period, the company reported EPS of $2.22 on revenue of $492.5 million. \n</p>\n<p>\n  The company also reported third-quarter net new business awards of $533.7 million, down from $611.5 million in the year-ago period. \n</p>\n<p>\n  The company said it was expecting 2024 revenue in the range of $2.09 billion to $2.13 billion, below prior guidance of a range between $2.125 billion and $2.175 billion. Also, Medpace said it was expecting 2024 EPS of $11.71 to $12.09. Previously, the company guided for 2024 EPS of $11.24 to $11.93. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2024 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace Holdings Shares Fall 11% After Company Reports 3Q Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace Holdings Shares Fall 11% After Company Reports 3Q Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-22 06:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Medpace Holdings were in the red in the after-hours market following the release of third-quarter financial results that showed the company raising its earnings-per-share guidance and cutting its revenue guidance for 2024. \n</p>\n<p>\n  After the bell, shares of the clinical contract research organization fell 11% to trade at $313.65. The stock finished Monday's regular session with a loss of less than 1%, closing at $352.92. \n</p>\n<p>\n  After the bell, Medpace reported third-quarter earnings per share of $3.01 on revenue of $533.3 million. In the year-ago period, the company reported EPS of $2.22 on revenue of $492.5 million. \n</p>\n<p>\n  The company also reported third-quarter net new business awards of $533.7 million, down from $611.5 million in the year-ago period. \n</p>\n<p>\n  The company said it was expecting 2024 revenue in the range of $2.09 billion to $2.13 billion, below prior guidance of a range between $2.125 billion and $2.175 billion. Also, Medpace said it was expecting 2024 EPS of $11.71 to $12.09. Previously, the company guided for 2024 EPS of $11.24 to $11.93. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2024 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2477430098","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477430098","pubTimestamp":1729551240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Medpace Holdings were in the red in the after-hours market following the release of third-quarter financial results that showed the company raising its earnings-per-share guidance and cutting its revenue guidance for 2024.After the bell, shares of the clinical contract research organization fell 11% to trade at $313.65. The stock finished Monday's regular session with a loss of less than 1%, closing at $352.92.After the bell, Medpace reported third-quarter earnings per share of $3.01 on revenue of $533.3 million. In the year-ago period, the company reported EPS of $2.22 on revenue of $492.5 million.The company also reported third-quarter net new business awards of $533.7 million, down from $611.5 million in the year-ago period.The company said it was expecting 2024 revenue in the range of $2.09 billion to $2.13 billion, below prior guidance of a range between $2.125 billion and $2.175 billion. Also, Medpace said it was expecting 2024 EPS of $11.71 to $12.09. Previously, the c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","MEDP":"Medpace Holdings Inc.","BK4588":"碎股","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC"},"translate_title":"Medpace Holdings公布第三季度业绩后股价下跌11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Medpace Holdings were in the red in the after-hours market following the release of third-quarter financial results that showed the company raising its earnings-per-share guidance and cutting its revenue guidance for 2024. \n\n\n  After the bell, shares of the clinical contract research organization fell 11% to trade at $313.65. The stock finished Monday's regular session with a loss of less than 1%, closing at $352.92. \n\n\n  After the bell, Medpace reported third-quarter earnings per share of $3.01 on revenue of $533.3 million. In the year-ago period, the company reported EPS of $2.22 on revenue of $492.5 million. \n\n\n  The company also reported third-quarter net new business awards of $533.7 million, down from $611.5 million in the year-ago period. \n\n\n  The company said it was expecting 2024 revenue in the range of $2.09 billion to $2.13 billion, below prior guidance of a range between $2.125 billion and $2.175 billion. Also, Medpace said it was expecting 2024 EPS of $11.71 to $12.09. Previously, the company guided for 2024 EPS of $11.24 to $11.93. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 21, 2024 18:54 ET (22:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}